Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
Samsung, Union Edge Closer to Deal as Strike Threat Looms 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
WEST LAFAYETTE, Ind., Sept. 20, 2016 -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company’s management team will present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, Sept. 27th, at 11:00 a.m. EDT. The conference will be held at the Sofitel New York in New York City.
A live audio webcast of the Company’s presentation can be accessed by visiting “Events & Presentations” under the Investors & News section of Endocyte’s website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company’s website for 90 days following the conference.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.
Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
